UNIVERSITY-OF-OULU
30.6.2020 06:07:12 CEST | Business Wire | Press release
The color of butterflies is mainly attributed to structural color as a result of diffraction of natural light. However, black color denotes trapping of sunlight within the butterfly scales. In some extreme cases, a butterfly will be rapidly de-iced through light-heat conversion within black scales on wings. Inspired by such a natural light harvesting process, scientists in the University of Oulu, Finland, research unit NANOMO carefully examined nanostructures of black scales obtained from different butterflies and assessed their light trapping abilities when placed on Si-based solar panels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005043/en/
Even with apparently the same dark color, butterfly scales have varied nanostructures depending on their species. For example, the morphology of Ornithoptera priamus scale consists of parallel V-shaped gullies formed between two ridges and connected by thin layers. This is very different from the scale structure of other three species, Tirumala limniace, Graphium doson, and Papilio protenor cramer, where the structures consist of round ridges spaced by arrays of 1, 2, and 3 holes. Correspondingly, light reflection on the black scales differs, with the one on the black part of Ornithoptera priamus owing minimum values ranging from 1-5% at the visible light region.
Using these structures as antireflective patterns will help sunlight harvesting on Si based photovoltaics. Computer simulated results showed that after placing these nanostructures on Si solar panels, surface backscattering decreased substantially. The scale structure of Ornithoptera priamus gave the best antireflection. Light reflection decreased from more than 35% on bare Si panel down to less than 5%. As a result, the short-circuit current, i.e. the largest current that can be obtained from the photovoltaic cell, was increased by 66%. Experimental realizations of such a strategy have also been proposed.
The latest research progress continues the world-leading role of NANOMO group in biomimicry. The unit pioneers in applying fundamental concepts in physics to applied photonics and solar energy harvesting. The research was coordinated by Professors Wei Cao and Marko Huttula, University of Oulu.
Considering the large volume of Si solar panels in use, it is foreseen that the butterfly wings can provide a major contribution to clean energy production.
Article:
Zhongjia Huang, Xinying Shi, Gang Wang, Petri Leukkunen, Marko Huttula, Wei Cao:
Antireflective design of Si-based photovoltaics via biomimicking structures on black butterfly scales, Solar Energy, Volume 4. DOI: https://doi.org/10.1016/j.solener.2020.05.031
sciencedirect.com 2020
https://www.sciencedirect.com/science/article/pii/S0038092X2030520X
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
